Chennai, June 22, 2022: Committed to continuous investment in the most advanced technologies in cancer care, Apollo Cancer Centres, ranked as the best private cancer hospital in India, in association with Datar Cancer Genetics brings a revolutionary blood test that can detect breast cancers at early stages in asymptomatic individuals with high accuracy, thus enabling timely diagnosis and treatment to save lives.
An increase in the number of breast cancer cases and the social construct associated with discussions of breast cancer has led to one of the most important developments in the history of technological advancement in the field of oncology. Led by the same urge to bring cancer conversations to the forefront, Apollo Cancer Centres, via this launch appeals to the women to get screened in the easiest way via a blood test to gain knowledge about their susceptibility to Breast Cancer. With an easy draw of a small quantity of blood, now, EasyCheck- Breast can help in the detection of breast cancer even before the first stage. The EasyCheck will be available across India on 22nd June at all Apollo Cancer Centres.
Commenting on the occasion, Dr Prathap Reddy, Founder & Chairman, Apollo Hospitals, said, “In line with our mission to spread awareness about early detection of cancers and offer world-class cancer treatment, the launch of EasyCheck Breast marks an important success towards quality technological advancements ensuring timely diagnosis and treatment to lower the mortality rate. This association with Datar Cancer Genetics has made a path-breaking achievement and at Apollo Cancer Centres, we are well equipped to diagnose breast cancers with the best in class advancements and treatments. I, humbly, request the caretakers of the family, the women of India, to step out for themselves and make sure to get themselves tested at least once a year to make sure you are safe from breast cancer. From diagnosis to treatment, Apollo Cancer Centres pledges to stand with their patients at all times and give them Tender Loving Care on the road to recovery.”
Speaking about the test, Mr Rajan Datar, Founder & Chairman, Datar Cancer Genetics, said, “Unfortunately, most cancers are detected at advanced stages which necessitate more intensive and expensive treatments which have a greater risk of debilitating side effects and treatment failures. EasyCheck- Breast is the culmination of years of collaborative international research and innovation and has been developed, tested, and validated on population-sized cohorts. A simple blood draw holds the promise of early cancer detection in asymptomatic individuals and opens the possibilities of successful treatments and improved survival.”
Commenting on the landmark development in diagnosis of cancer at an early stage, Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals, said, “At Apollo, patient-centricity is at the core of our approach, be it in diagnosis, treatment, or care post recovery. Now, with the introduction of the innovative EasyCheck Breast, it is a giant leap forward in enabling early and easy identification of breast cancer, in a very convenient manner. According to our experts, approximately 70% of women in India are diagnosed at a late stage and we are hopeful that EasyCheck Breast will contribute to lowering this statistic significantly”.
On the occasion, Mr. Dinesh Madhavan, President Group Oncology and International, Apollo Hospital Enterprises Ltd said, “With the launch of Easy Check Breast, Apollo Cancer Centres and Datar Genetics is committed to ensure that we diagnose cancer at the earliest and this is the first step in winning over cancer. The late diagnosis of breast cancer remains the sole cause of high mortality rate in women with breast cancer in India. With Easy Check Breast, we address this root cause and make it earlier, easier. “
Breast cancer is the most common malignancy among women globally. It has now surpassed lung cancer as the leading cause of global cancer incidence in 2020, with an estimated 2.3 million new cases, representing 11.7% of all cancer cases. Epidemiological studies have shown that the global burden of Breast Cancer is expected to cross almost 2 million by the year 2030. In India, the incidence has increased significantly, almost by 50%, between 1965 and 1985. The estimated number of incident cases in India in 2016 was 118000. As per data, in India, Breast Cancer accounted for 13.5% (178361) of all cancer cases and 10.6% (90408) of all deaths in 2020.
In line with the mission to spread awareness about cancer & regular screening for early detection with EasyCheck- Breast, Apollo Cancer aims at addressing the pressing need for the right knowledge about early diagnosis, and holistic treatment in cancer care.
About Apollo Cancer Centres – www.apollocancercentres.com
THE CANCER CARE LEGACY: BREATHING HOPE INTO LIVES FOR OVER 28 YEARS
Cancer care today means 360-degree comprehensive care, which requires commitment, expertise and an indomitable spirit from the cancer specialists
Apollo Cancer Centres- are present across 14 cities and has 1000 dedicated beds, over 240 oncologists to oversee delivery of high-end precision Oncology Therapy. Our oncologists deliver world-class cancer care following an organ-based practice under competent Cancer Management Teams. This helps us in delivering exemplary treatment to the patient in an environment which has consistently delivered an international standard of clinical outcomes.
Today people from 147 countries come to India for cancer treatment at Apollo Cancer Centres. With the first & only Pencil Beam Proton Therapy Centre in South Asia & Middle East, Apollo Cancer Centres has all that is needed to strengthen the battle against cancer.
About Datar Cancer Genetics
Datar Cancer Genetics is a leading cancer research corporation specializing in non-invasive techniques for better diagnosis, treatment decisions, and management of cancer. The Company’s state-of-the-art cancer research center is NABL, ISO, CAP and CLIA accredited. The Company serves cancer patients in the UK, European Union, United States, GCC and India.